Zealand Pharma - Stærke Fase-3 data og stor kapitalrejsning
-
Zealand Pharma kunne 30. september annoncere positive resultater fra fase 3-forsøg med glepaglutid hos patienter med korttarmssyndrom. Derudover har virksomheden netop sikret sig 786 mio. kr. fra salg af nye aktier. Dermed står Zealand Pharma stærkt i kommende forhandlinger med en potentiel partner og til udvikling af deres pipeline - som også indeholder spændende produkter inden for fedme. Hør mere i dette interview, hvor Helge Larsen et taget ud til Zealand Pharma for at tale med CEO Adam Steensberg.
Disclaimer: Zealand Pharma har betalt ir-samarbejde med ProInvestor.com.
-
Man kan i hvert fald sige, at kapitalrejsningen var flot og blev pænt modtaget. Den giver håb om, at investorerne ikke har afskrevet biotek fuldstændig.
-
Zealand Pharma major shareholder announcement: Van Herk Investments
Company announcement - No. 46 / 2022
Zealand Pharma major shareholder announcement: Van Herk Investments
Copenhagen, Denmark and Boston, MA, 10 October 2022 - Zealand Pharma A/S ("Zealand") (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt of notification dated 10 October 2022 pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders:
As from 7 October 2022 Van Herk Investments B.V. (Dutch registration no. 59055057) holds nominally 7,630,244 shares (each share carrying one vote) in Zealand Pharma A/S, corresponding to 14,81% of the total share capital and total voting rights Zealand Pharma A/S.
Van Herk Investments B.V. is 100% owned by Van Herk Investments THI B.V. which is 100% owned by Van Herk Private Equity Investments B.V. (Dutch registration no. 58894543, which is ultimately owned and controlled by Mr. Adrianus van Herk.
Van Herk Management Services B.V. (Dutch registration no. 24377325) controls and exercises the voting rights on behalf of Van Herk Investments B.V., and accordingly, Van Herk Management Services B.V controls and exercises the voting rights on nominally 7,630,244 shares (each share carrying one vote), corresponding to 14,81% of the total share capital and total voting rights in Zealand Pharma A/S.
Van Herk Management Services B.V., is controlled by OGBB A. van Herk B.V. (Dutch registration no. 24160906), which is controlled by A. van Herk Holding B.V. (Dutch registration no. 24160780), which is ultimately controlled by Mr. Adrianus van Herk.
Please see further details in the attached notification forms.
#
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. In addition, license collaborations with Boehringer Ingelheim and AstraZeneca create opportunities for more patients to potentially benefit from Zealand-invented peptide investigational agents currently in development.
Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. that includes Boston. For more information about Zealand's business and activities, please visit www.zealandpharma.com.
Contact:
Anna Krassowska, PhD
Vice President, Investor Relations & Corporate Communications
Zealand Pharma
Email: [email protected]David Rosen (U.S. Media)
Argot Partners
Email: [email protected] -
Zealand Pharma major shareholder announcement: Polar Capital
Zealand Pharma major shareholder announcement: Polar Capital
Company announcement – No. 47 / 2022 Zealand Pharma major shareholder announcement: Polar Capital Copenhagen, Denmark and Boston, MA, 11 October...
GlobeNewswire News Room (www.globenewswire.com)
Zealand Pharma: Polar Capital ejer 11,51 pct. aktier.
-
Company announcement - No. 47 / 2022
Zealand Pharma major shareholder announcement: Polar Capital
Copenhagen, Denmark and Boston, MA, 11 October 2022 - Zealand Pharma A/S ("Zealand") (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt on 11 October 2022 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders:
As of 10 October 2022, Polar Capital LLP holds nominally 5,930,317 shares (each share carrying one vote) in Zealand Pharma A/S, corresponding to 11.51% of the total share capital and total voting rights in Zealand Pharma A/S.
Please see further details in the attached notification form.
#
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. In addition, license collaborations with Boehringer Ingelheim and AstraZeneca create opportunities for more patients to potentially benefit from Zealand-invented peptide investigational agents currently in development.
Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. that includes Boston. For more information about Zealand's business and activities, please visit www.zealandpharma.com.
Contact:
Anna Krassowska, PhD
Vice President, Investor Relations & Corporate Communications
Zealand Pharma
Email: [email protected]David Rosen (U.S. Media)
Argot Partners
Email: [email protected] -
Zealand Pharma/Jefferies: Kursmål hæves til 205 kr. fra 165 kr. - NY
12/10 06:56
Zealand Pharma har fået løftet sit kursmål til 205 kr. fra 165 kr. hos Jefferies. Anbefalingen lyder fortsat "køb".
Det fremgår af et notat fra banken, efter at Zealand i de seneste par uger har præsenteret succesrige fase 3-data med lægemiddelkandidaten Glepaglutid til behandling af korttarmssyndrom og har rejst et stort trecifret millionbeløb.
- Positive fase 3-data med Glepaglutid i den sjældne sygdom korttarmssyndrom åbner mulighed for en kommerciel aftale, mens investorfokus sandsynligvis nu vil skifte til Zealands interessante tidlige portefølje af diabetes- og fedmemidler og peptidplatformen, skriver Jefferies' analyseteam.
Børshuset ser mulighed for yderligere samarbejder og partnerskaber inden for diabetes og fedme, og/eller at Zealand ender med at blive købt.
Aktien steg tirsdag 4,3 pct. til 169,80 kr.
.\˙ MarketWire
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind